Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

MeningitisMeningococcal InfectionsMeningococcal Meningitis

Phase 2

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

CompletedNCT03205358

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2015-03-31End: 2015-08-19Updated: 2022-04-04

Phase 3

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

CompletedNCT02955797

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2017-02-24End: 2017-10-26Updated: 2022-04-05

Related Papers

Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children

Infectious Diseases and Therapy2025-04-017 citations

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Human Vaccines & Immunotherapeutics2021-06-0416 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)<i>vs</i>. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study

Epidemiology and Infection2021-01-0120 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study

Epidemiology and Infection2021-01-0114 citations

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study

Human Vaccines & Immunotherapeutics2020-04-0136 citations